Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study.
ASCVD
Age
Atherosclerotic cardiovascular disease
Gender
Risk score
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
09 04 2022
09 04 2022
Historique:
received:
19
09
2021
accepted:
31
03
2022
entrez:
10
4
2022
pubmed:
11
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Atherosclerotic cardiovascular disease (ASCVD) continues to be the first cause of mortality globally. Effective preventive strategies require focused efforts to clarify ASCVD risk factors in different subgroups of a population. This study aimed to identify individuals at higher risk of ASCVD among Shiraz University employees to guide decision-making for primary prevention. This cohort-based cross-sectional study was conducted on data of 1191 participants (25-70 years old) from Shiraz University employees selected by systematic random sampling. The 10-year ASCVD risk was calculated with an ASCVD risk score estimator developed by the American College of Cardiology/American Heart Association (ACC/AHA). To analyze the data, descriptive and chi-square tests were used. All statistical analyses were conducted using the SPSS version 16.0 software. The p-value < 0.05 was considered a significant level. This study demonstrated that 75.3% of the participants had low risk scores, whereas 13.2% and 2.5% of them had intermediate and high risk scores, respectively. Additionally, it revealed that among women 93.7%, 2.7%, and 0.6% had low intermediate and had high risk scores, respectively, whereas among men, 61.5%, 21.1%, and 3.9% had low intermediate and high risk scores, respectively. Based on the results of the chi-square test, men were significantly more prone to ASCVD (38.5%) than women (6.3%) were. Interestingly, 40.9% of known cases of hypertension had uncontrolled blood pressure, and 62.5% of individuals without any history of hypertension, who were considered new cases of hypertension, had abnormal blood pressure. Furthermore, 38.5% of diabetic patients and 1.6% of people who did not have a history of diabetes had abnormal serum fasting blood sugar. It was revealed that nearly 15.7% of participants were at intermediate and high risk of developing ASCVD in the next 10 years with greater risk in men. Considerably, some of hypertensive and diabetic participants had uncontrolled blood pressure and blood sugar levels, respectively. New cases of diabetes and hypertension were also recognized in our study. Therefore, to address the primary prevention of ASCVD in this population, it is necessary to have plans for targeted interventions, which can be effective in modifying their risk factors.
Sections du résumé
BACKGROUND
Atherosclerotic cardiovascular disease (ASCVD) continues to be the first cause of mortality globally. Effective preventive strategies require focused efforts to clarify ASCVD risk factors in different subgroups of a population. This study aimed to identify individuals at higher risk of ASCVD among Shiraz University employees to guide decision-making for primary prevention.
METHODS
This cohort-based cross-sectional study was conducted on data of 1191 participants (25-70 years old) from Shiraz University employees selected by systematic random sampling. The 10-year ASCVD risk was calculated with an ASCVD risk score estimator developed by the American College of Cardiology/American Heart Association (ACC/AHA). To analyze the data, descriptive and chi-square tests were used. All statistical analyses were conducted using the SPSS version 16.0 software. The p-value < 0.05 was considered a significant level.
RESULTS
This study demonstrated that 75.3% of the participants had low risk scores, whereas 13.2% and 2.5% of them had intermediate and high risk scores, respectively. Additionally, it revealed that among women 93.7%, 2.7%, and 0.6% had low intermediate and had high risk scores, respectively, whereas among men, 61.5%, 21.1%, and 3.9% had low intermediate and high risk scores, respectively. Based on the results of the chi-square test, men were significantly more prone to ASCVD (38.5%) than women (6.3%) were. Interestingly, 40.9% of known cases of hypertension had uncontrolled blood pressure, and 62.5% of individuals without any history of hypertension, who were considered new cases of hypertension, had abnormal blood pressure. Furthermore, 38.5% of diabetic patients and 1.6% of people who did not have a history of diabetes had abnormal serum fasting blood sugar.
CONCLUSION
It was revealed that nearly 15.7% of participants were at intermediate and high risk of developing ASCVD in the next 10 years with greater risk in men. Considerably, some of hypertensive and diabetic participants had uncontrolled blood pressure and blood sugar levels, respectively. New cases of diabetes and hypertension were also recognized in our study. Therefore, to address the primary prevention of ASCVD in this population, it is necessary to have plans for targeted interventions, which can be effective in modifying their risk factors.
Identifiants
pubmed: 35397522
doi: 10.1186/s12872-022-02601-0
pii: 10.1186/s12872-022-02601-0
pmc: PMC8994278
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
162Informations de copyright
© 2022. The Author(s).
Références
Curr Opin Lipidol. 2012 Dec;23(6):532-9
pubmed: 23160400
J Am Coll Cardiol. 2004 May 19;43(10):1791-6
pubmed: 15145101
J Am Coll Cardiol. 2018 May 15;71(19):2199-2269
pubmed: 29146533
Mater Sociomed. 2015 Jun;27(3):158-62
pubmed: 26236160
Circulation. 2016 Nov 8;134(19):1430-1440
pubmed: 27682885
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
PLoS One. 2017 Feb 24;12(2):e0172897
pubmed: 28235058
Oxid Med Cell Longev. 2020 Sep 15;2020:5245308
pubmed: 33014272
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
Ren Fail. 2021 Dec;43(1):477-487
pubmed: 33685340
JAMA. 2014 Apr 9;311(14):1406-15
pubmed: 24682252
J Am Heart Assoc. 2015 Apr 17;4(4):
pubmed: 25888372
Am Heart J. 1991 Jan;121(1 Pt 2):293-8
pubmed: 1985385
J Am Heart Assoc. 2014 Oct 02;3(5):e001117
pubmed: 25277669
ARYA Atheroscler. 2018 Jul;14(4):163-168
pubmed: 30627192
BMJ Open. 2019 Apr 3;9(4):e026317
pubmed: 30948600
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
J Am Coll Cardiol. 2010 Mar 23;55(12):1169-1177
pubmed: 20298922
Arch Iran Med. 2019 Apr 01;22(4):204-210
pubmed: 31126179
N Engl J Med. 2008 Nov 20;359(21):2195-207
pubmed: 18997196
Lancet. 1980 Jun 28;1(8183):1373-6
pubmed: 6104171
Am J Med. 2011 Feb;124(2):95-102
pubmed: 21295188
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Diabetes Care. 2016 Jan;39 Suppl 1:S60-71
pubmed: 26696684
Heart. 2011 Mar;97(6):442-4
pubmed: 21339319
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350
pubmed: 30423393
Circulation. 2019 Sep 10;140(11):e563-e595
pubmed: 30879339
Biomed Res Int. 2020 Aug 11;2020:8179795
pubmed: 32851088
BMC Public Health. 2020 Feb 3;20(1):166
pubmed: 32013917
BMJ. 2003 Jun 28;326(7404):1419
pubmed: 12829553
Circulation. 1979 Jan;59(1):8-13
pubmed: 758126
Front Endocrinol (Lausanne). 2020 Feb 26;11:42
pubmed: 32174887
J Am Coll Cardiol. 2016 Oct 11;68(15):1690-1697
pubmed: 27712783
Curr Hypertens Rev. 2019;15(2):113-122
pubmed: 30657043
J Pak Med Assoc. 2015 Aug;65(8):907-8
pubmed: 26228345
Lancet. 2005 Jan 29-Feb 4;365(9457):434-41
pubmed: 15680460
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959
pubmed: 24239921
Pharmacol Ther. 2010 Jun;126(3):314-45
pubmed: 20153365
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
J Am Coll Cardiol. 2009 Sep 29;54(14):1209-27
pubmed: 19778661
N Engl J Med. 1992 Jan 30;326(5):310-8
pubmed: 1728735
Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):11-29
pubmed: 12920698